Biopolym. Cell. 2004; 20(3):182-192 .
Evaluation of renaturation methods for industrial obtaining of recombinant proteins from Escherichia coli inclusion bodies in biologically active form
1Gilchuk P. V.
  1. Institute of Molecular Biology and Genetics, NAS of Ukraine
    150, Akademika Zabolotnoho Str., Kyiv, Ukraine, 03680


One of the widely used strategies for the production of recombinant proteins in Escherichia coli cells is their accumulation as insoluble cytoplasmatic aggregates-inclusion bodies-during the expression. The advantage of such synthesis is determined by the high leves of accumulation and purity of the target protein as well as by the possibility to carry out successful renaturation and to obtain active product from insoluble aggregates under conditions in vitro. The main problem hindering industrialization of this process is caused by the absence of universal renaturation schemes, as refolding of the recombinant proteins is an empiric process and needs the development of unique protocols for individual proteins. Study on main aggregation modes and folding processes in vivo allowed developing effective approaches for the refolding of many recombinant proteins. The evaluation of some contemporary methods of protein refolding is given in the review. The main strategies, that can be used for the industrial obtaining of proteins from bacterial inclusion bodies, are discussed. Recent achievements in the area of refolding recombinant proteins that contain disulfide bonds (oxidative refolding) are briefly described. The reasons of protein aggregation in the process of in vitro renaturation as well as the approaches used for increasing yield of correctly refolded protein are analyzed.


[1] Mashko SV. Optimization expression of foreign genes in E. coli cells. Biotekhnologiya. 1998. 6:3-23.
[2] Rudolph R, Lilie H. In vitro folding of inclusion body proteins. FASEB J. 1996;10(1):49-56.
[3] Clark EDB. Refolding of recombinant proteins. Curr Opin Biotechnol. 1998;9(2):157-63.
[4] Clark ED. Protein refolding for industrial processes. Curr Opin Biotechnol. 2001;12(2):202-7.
[5] Li M, Su ZG, Janson JC. In vitro protein refolding by chromatographic procedures. Protein Expr Purif. 2004;33(1):1-10.
[6] The QIAexpressionist. A handbook for high-level expression and purification 6-His-tagget proteins, New York: Qiagen 2000; p. 14.
[7] Demchenko AP. Recognition between flexible protein molecules: induced and assisted folding. J Mol Recognit. 2001;14(1):42-61.
[8] Horowitz PM. Ironing out the protein folding problem? Nat Biotechnol. 1999;17(2):136-7.
[9] Tsumoto K, Ejima D, Kumagai I, Arakawa T. Practical considerations in refolding proteins from inclusion bodies. Protein Expr Purif. 2003;28(1):1-8.
[10] Cowley DJ, Mackin RB. Expression, purification and characterization of recombinant human proinsulin. FEBS Lett. 1997;402(2-3):124-30.
[11] Burgess RR. Purification of overproduced Escherichia coli RNA polymerase sigma factors by solubilizing inclusion bodies and refolding from Sarkosyl. Methods Enzymol. 1996;273:145-9.
[12] Rozema D, Gellman SH. Artificial chaperone-assisted refolding of denatured-reduced lysozyme: modulation of the competition between renaturation and aggregation. Biochemistry. 1996;35(49):15760-71.
[13] Choi S., Kim J., Lee Y., Jang Y.-J., Pastan I., Choe M. A divalent immunotoxin formed by the disulfide bond between hinge regions of fab domain. Bull Korean Chem Soc. 2001; 22 (12):1361-1365.
[14] Simmons T, Newhouse YM, Arnold KS, Innerarity TL, Weisgraber KH. Human low density lipoprotein receptor fragment. Successful refolding of a functionally active ligand-binding domain produced in Escherichia coli. J Biol Chem. 1997;272(41):25531-6.
[15] Middelberg AP. Preparative protein refolding. Trends Biotechnol. 2002;20(10):437-43.
[16] Ptitsyn OB, Bychkova VE, Uversky VN. Kinetic and equilibrium folding intermediates. Philos Trans R Soc Lond B Biol Sci. 1995;348(1323):35-41.
[17] De Bernardez Clark E, Hevehan D, Szela S, Maachupalli-Reddy J. Oxidative renaturation of hen egg-white lysozyme. Folding vs aggregation. Biotechnol Prog. 1998;14(1):47-54.
[18] Wall JG, Pluckthun A. The hierarchy of mutations influencing the folding of antibody domains in Escherichia coli. Protein Eng. 1999;12(7):605-11.
[19] Knappik A, Pluckthun A. Engineered turns of a recombinant antibody improve its in vivo folding. rotein Eng. 1995;8(1):81-9.
[20] Bollag D.M., Daniel M. Protein Methods, New York 1996; p. 415.
[21] Glockshuber R, Schmidt T, Pluckthun A. The disulfide bonds in antibody variable domains: effects on stability, folding in vitro, and functional expression in Escherichia coli. Biochemistry. 1992;31(5):1270-9.
[22] Raina S, Missiakas D. Making and breaking disulfide bonds. Annu Rev Microbiol. 1997;51:179-202.
[23] Ohage E, Steipe B. Intrabody construction and expression. I. The critical role of VL domain stability. J Mol Biol. 1999;291(5):1119-28.
[24] Wulfing C, Pluckthun A. Protein folding in the periplasm of Escherichia coli. Mol Microbiol. 1994;12(5):685-92.
[25] Pluckthun A. Antibodies from Escherichia coli. The pharmacology of monoclonal antibodies, Eds M. Rosenberg, G. P. Moore.-Berlin: Springer 1995; p. 269-315.
[26] Martineau P, Jones P, Winter G. Expression of an antibody fragment at high levels in the bacterial cytoplasm. J Mol Biol. 1998;280(1):117-27.
[27] pET System Manual, New York: Novagen 1999; p. 15.
[28] Kurucz I, Titus JA, Jost CR, Segal DM. Correct disulfide pairing and efficient refolding of detergent-solubilized single-chain Fv proteins from bacterial inclusion bodies. Mol Immunol. 1995;32(17-18):1443-52.
[29] Berdichevsky Y, Lamed R, Frenkel D, Gophna U, Bayer EA, Yaron S, Shoham Y, Benhar I. Matrix-assisted refolding of single-chain Fv- cellulose binding domain fusion proteins. Protein Expr Purif. 1999;17(2):249-59.
[30] Blank K, Lindner P, Diefenbach B, Pl?ckthun A. Self-immobilizing recombinant antibody fragments for immunoaffinity chromatography: generic, parallel, and scalable protein purification. Protein Expr Purif. 2002;24(2):313-22.
[31] Stevens RC. Design of high-throughput methods of protein production for structural biology. Structure. 2000;8(9):R177-85.
[32] Buchner J, Pastan I, Brinkmann U. A method for increasing the yield of properly folded recombinant fusion proteins: single-chain immunotoxins from renaturation of bacterial inclusion bodies. Anal Biochem. 1992;205(2):263-70.
[33] Lindner P., Guth B., Wulfing C., Krebber C., Steipe B., Muller F., Pluckthun, A. Purification of native proteins from the cytoplasm and periplasm of Escherichia coli using IMAC and histidine tails: A comparison of proteins and protocols () Methods. 1992; 4 (1):41-56.
[34] Schmid G. Cyclodextrin glycosyltransferase production: yield enhancement by overexpression of cloned genes. Trends in Biotechnology. 1989;7 (9):244-248.
[35] Cardamone M, Puri NK, Brandon MR. Comparing the refolding and reoxidation of recombinant porcine growth hormone from a urea denatured state and from Escherichia coli inclusion bodies. Biochemistry. 1995;34(17):5773-94.
[36] Dubnovitsky AP, Kravchuk ZI, Chumanevich AA, Cozzi A, Arosio P, Martsev SP. Expression, refolding, and ferritin-binding activity of the isolated VL-domain of monoclonal antibody F11. Biochemistry (Mosc). 2000;65(9):1011-8.
[37] Altamirano MM, Golbik R, Zahn R, Buckle AM, Fersht AR. Refolding chromatography with immobilized mini-chaperones. Proc Natl Acad Sci U S A. 1997;94(8):3576-8.
[38] Dubrovsky A. L., Savinskaya L. A., Kornelyuk A. I. Cloning and bacterial expression of the cytokine-like noncatalytic domain of bovine tyrosyl-tRNA synthetase. Biopolym Cell. 1998; 14(5):449-452.